Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is a prevalent bone cancer in children and adolescents.
• The underlying molecular mechanisms of osteosarcoma development are not fully understood.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer.

Purpose of the Study:

• To identify novel dysregulated lncRNAs in osteosarcoma.
• To investigate the functional role of a newly identified lncRNA, Lnc-MAP6-1:3, in osteosarcoma.
• To explore the potential molecular pathways influenced by Lnc-MAP6-1:3 in osteosarcoma progression.

Main Methods:

• RNA sequencing (RNA-seq) to identify dysregulated lncRNAs.
• Gene knockdown techniques to reduce Lnc-MAP6-1:3 expression.
• Reverse transcription polymerase chain reaction (RT-PCR) for expression analysis.
• In vitro assays to assess cell proliferation, colony formation, and apoptosis.
• Western blotting to analyze protein expression in signaling pathways.

Main Results:

• A novel lncRNA, Lnc-MAP6-1:3, was found to be highly expressed in osteosarcoma.
• Knockdown of Lnc-MAP6-1:3 significantly suppressed osteosarcoma cell proliferation and colony formation in vitro.
• Lnc-MAP6-1:3 knockdown promoted apoptosis in osteosarcoma cells.
• Lnc-MAP6-1:3 influences osteosarcoma malignancy potentially through the Bax/Bcl-2 and Wnt/β-catenin signaling pathways.

Conclusions:

• Lnc-MAP6-1:3 is a novel oncogenic lncRNA implicated in osteosarcoma progression.
• Targeting Lnc-MAP6-1:3 may offer a new therapeutic strategy for osteosarcoma.
• Further research into Lnc-MAP6-1:3's role in signaling pathways could yield novel diagnostic and therapeutic targets for osteosarcoma.